You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 4, April 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Trial
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Diabetic Retinopathy
 •Macular Disorders
 •Ophthalmological Procedures, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Comparison of the Modified Early Treatment Diabetic Retinopathy Study and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular Edema

Writing Committee for the Diabetic Retinopathy Clinical Research Network

Arch Ophthalmol. 2007;125(4):469-480.

Objective  To compare 2 laser photocoagulation techniques for treatment of diabetic macular edema: the modified Early Treatment Diabetic Retinopathy Study (ETDRS) direct/grid photocoagulation technique and a potentially milder (but potentially more extensive) mild macular grid (MMG) laser technique in which microaneurysms are not treated directly and small mild burns are placed throughout the macula, whether or not edema is present.

Methods  Two hundred sixty-three subjects (mean age, 59 years) with previously untreated diabetic macular edema were randomly assigned to receive laser photocoagulation by either the modified ETDRS (162 eyes) or MMG (161 eyes) technique. Visual acuity, fundus photographs, and optical coherence tomography measurements were obtained at baseline and at 3.5, 8, and 12 months. Treatment was repeated if diabetic macular edema persisted.

Main Outcome Measure  Change in optical coherence tomography measurements at 12-month follow-up.

Results  Among eyes with a baseline central subfield thickness of 250 µm or greater, central subfield thickening decreased by an average of 88 µm in the modified ETDRS group and by 49 µm in the MMG group at 12-month follow-up (adjusted mean difference, 33 µm; 95% confidence interval, 5-61 µm; P = .02). Weighted inner zone thickening by optical coherence tomography decreased by 42 µm in the modified ETDRS group and by 28 µm in the MMG group (adjusted mean difference, 14 µm; 95% confidence interval, 1-27 µm; P = .04); maximum retinal thickening (maximum thickening of the central and 4 inner subfields) decreased by 66 and 39 µm, respectively (adjusted mean difference, 27 µm; 95% confidence interval, 6-47 µm; P = .01), and retinal volume decreased by 0.8 and 0.4 mm3, respectively (adjusted mean difference, 0.3 mm3; 95% confidence interval, 0.02-0.53 mm3; P = .03). At 12 months, the mean change in visual acuity was 0 letters in the modified ETDRS group and 2 letters worse in the MMG group (adjusted mean difference, 2 letters; 95% confidence interval, –0.5 to 5 letters; P = .10).

Conclusions  At 12 months after treatment, the MMG technique was less effective at reducing optical coherence tomography–measured retinal thickening than the more extensively evaluated current modified ETDRS laser photocoagulation approach. However, the visual acuity outcome with both approaches is not substantially different. Given these findings, a larger long-term trial of the MMG technique is not justified.

Application to Clinical Practice  Modified ETDRS focal photocoagulation should continue to be a standard approach for treating diabetic macular edema.

Trial Registration  clinicaltrials.gov Identifier: NCT00071773.


Writing Committee: The lead authors are Donald S. Fong, MD, (lead author) and Samara F. Strauber, MS. Additional writing committee members are Lloyd Paul Aiello, MD, PhDl; Roy W. Beck, MD, PhD; David G. Callanan, MD; Ronald P. Danis, MD; Matthew D. Davis, MD; Stephen S. Feman, MD; Frederick Ferris, MD; Scott M. Friedman, MD; Charles A. Garcia, MD; Adam R. Glassman, MS; Dennis P. Han, MD; Darma le, MD; Craig Kollman, PhD; Andreas K. Lauer, MD; Franco M. Recchia, MD; and Sharon D. Solomon, MD.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fundus autofluorescence and Fourier-domain optical coherence tomography imaging of 10 and 20 millisecond Pascal retinal photocoagulation treatment
Muqit et al.
Br J Ophthalmol 2009;93:518-525.
ABSTRACT | FULL TEXT  

Three-Year Follow-up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular Edema
Diabetic Retinopathy Clinical Research Network (DR
Arch Ophthalmol 2009;127:245-251.
ABSTRACT | FULL TEXT  

Comparison of Optical Coherence Tomography in Diabetic Macular Edema, with and without Reading Center Manual Grading from a Clinical Trials Perspective
Glassman et al.
IOVS 2009;50:560-566.
ABSTRACT | FULL TEXT  

Interventions for diabetic macular oedema: a systematic review of the literature
O'Doherty et al.
Br J Ophthalmol 2008;92:1581-1590.
ABSTRACT | FULL TEXT  

Comparison of Time-Domain OCT and Fundus Photographic Assessments of Retinal Thickening in Eyes with Diabetic Macular Edema
Davis et al.
IOVS 2008;49:1745-1752.
ABSTRACT | FULL TEXT  

Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.